Ascendia

  MARKET NEWS

Actylis Announces Appointment of Scott Thomson as Chief Executive Officer
Zymeworks Announces FDA Clearance of IND Application for  Novel 2+1 T-Cell Targeting Bispecific Antibody For Mesothelin-Expressing Cancers
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data
FOXO Technologies Enters Agreements to Acquire Healthcare Operations From Rennova Health, Inc.
LIXTE Biotechnology Announces Collaboration on New Colon Cancer Clinical Trial
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for AI-Designed Personalized Cancer Vaccine 
Grifols’ Biotest Receives FDA Approval for Innovative Immunoglobulin
Biosplice Announces Collaboration With Novo Nordisk in Diabetes

  EXPERT CONTENT & RESOURCES

Lyophilization Trends in Pharma & Biopharma Drug Development

Lyophilization Trends in Pharma & Biopharma Drug Development

This 30-page eBook is exactly what you have been looking for. Find out what is driving the lyophilization market and how working with a CDMO will save time and money and help you comply with increasing regulatory requirements.

Premium Cell Culture Ingredients From Actylis

Premium Cell Culture Ingredients From Actylis

Thanks to our many GMP manufacturing sites located in North America, Europe and Asia we can provide the critical ingredients for your Biopharma manufacturing applications.

  FEATURED EDITORIAL

  COMPANY PROFILE

Nanjing Well Pharmaceutical Group Co., Ltd., a high-tech enterprise from China specializing in R&D, manufacturing, and supplying pharmaceutical excipients and APIs. Our factory is located in Nanjing National New Materials Technology Park. We are currently one of the largest suppliers of pharmaceutical excipients for solid, semi-solid, and liquid preparations in China, with annual sales of more than 10,000 tons and sales of more than 40 million US dollars. We maintain long-term and stable cooperation with more than 1,000 pharmaceutical companies at home and abroad, such as Johnson & Johnson, GSK, Novartis, Bayer, and other multinational pharmaceutical companies. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants

WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants

Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at the desired site of action.

Download our latest white paper, jointly authored with MeltPrep, to …

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.

Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 26 – Excipients
July 3 – Controlled Release